Exploring promoter silencing and re-expression of SH3GL2/endophilin A1 in urothelial cancer
INTRODUCTION: Bladder cancer (BC) is highly prevalent. It presents as either non-muscle invasive or muscle-invasive disease. The prognosis of muscle invasive disease is poor, with a 5-year survival rate of less than 50%. Treatment approaches for both types of BC have not advanced much in the last fe...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/30904 |